All In Biotech

Drug Trial Radar · NCT04887532

A Trial of HR19042 Capsule in Healthy Chinese Subjects

Safety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Sep 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Jul 1, 2021

Primary completion

Jul 27, 2021

Study completion Jul 27, 2021

Sponsor

Sponsor type
Industry
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety and pharmacokinetics of HR19042 capsule after single administration in healthy Chinese subjects. To explore the pharmacokinetic characteristics and safety of HR19042 capsule in healthy Chinese subjects.

Conditions

  • Primary IgA Nephropathy

Interventions

  • HR19042 capsuleDrug

    phase 1 :8mg; phase 2:12mg; phase 3:16mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 0-24 hours
  2. AUC0-t;Time frame: 0-24 hours
  3. AUC0-∞Time frame: 0 hour to 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.